Free shipping on all orders over $ 500


Cat. No. M2112
LY2835219 Structure

ABEMACICLIB, CDK4/6 dual inhibitor

Size Price Availability Quantity
Free Sample (0.5-1 mg)  USD 0 In stock
10mg USD 100 In stock
50mg USD 280 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control
Biological Activity

LY2835219 is a potent and selective CDK4/6 dual inhibitor with potential antineoplastic activity. CDK4/6 dual inhibitor LY2835219 has been shown in vitro to be a selective ATP-competitive inhibitor of CDK4/6 that inhibits phosphorylation of the Rb tumor suppressor protein and thereby induces G1 cell cycle arrest. Inhibition of Rb phosphorylation prevents CDK-mediated G1-S phase transition, thereby arresting the cell cycle in the G1 phase, suppressing DNA synthesis and inhibiting cancer cell growth. LY2835219 is being investigated in a phase I clinical trial and in a clinical trial for the treatment of mantle cell lymphoma.

Product Citations
Customer Product Validations & Biological Datas
Source Cancer Cell (2018). Figure 5. abemaciclib (Abmole Bioscience, Houston, USA)
Method oral gavage
Cell Lines Mice
Concentrations 50 mg/kg
Incubation Time
Results Mice treated with IRN + VCR had stable disease (SD), whereas mice treated with either palbociclib + trametinib or abemaciclib + trametinib exhibited progressive disease.
Source Invest New Drugs (2014). Figure 2. LY2835219
Method flow cytometry
Cell Lines MCF10A cells
Concentrations 5 μM
Incubation Time 24-hour
Results LY2835219 induced a G1 arrest in Rb-proficient MDA-MB-231 breast cancer cells, whereas no such effect was seen in Rb-deficient MDA-MB-468 breast cancer cells at compound concentrations up to 2,500 nmol/L
Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Chemical Information
Molecular Weight 602.7
Formula C27H32F2N8.CH4O3S
CAS Number 1231930-82-7
Purity >99%
Solubility DMSO 73 mg/mL
Storage at -20°C
Related CDK Products

BSJ-03-123 is a potent and novel CDK6-selective small-molecule degrader.


THZ2 (an analog of THZ1) is a potent and selective CDK7 inhibitor which overcomes the instability of THZ1 in vivo (IC50s: CDK7=13.9 nM; TNBC cells=10 nM).


LY-3177833 is a potent and selective inhibitor of CDC7 with IC50 of 3.3 nM.


Voruciclib (P1446A-05) is a protein kinase inhibitor specific for the cyclin-dependent kinase 4 (CDK4) with IC50s of 90nM, 25nM, and 22nM for CDK4-CyclinD1, CDK1-Cyclin B, and CDK9-Cyclin T, respectively.


CVT-313 is a potent and selective inhibitor of CDK2 that prevents neointimal proliferation, which has an IC50 of 0.5 microM in vitro.

Abmole Inhibitor Catalog 2017

Keywords: LY2835219, ABEMACICLIB, CDK4/6 dual inhibitor supplier, CDK, inhibitors

Contact Us

Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2017 AbMole BioScience. All Rights Reserved.